iTR (Induced Tissue Regeneration)

Talk by @DrMichaelWest of @agexthera at @LongevityDublin summit. "What do I expect to see in aging research? I think it’s rather dramatic, actually, what I’m expecting to see. (deadly serious look at the audience) Beyond what you can imagine, really.” youtube.com/watch?v=r8ZKGP…

Great article about Lamins, proteins that help repair DNA breaks & stabilize chromosomes, preventing aging caused by epigenetic drift When Lamins are missing, vital chromosomal loop structures that regulate genes unravel & aging accelerates cell.com/cell-reports/f…

Longevity NEWS: Anti-aging biotech @newlimit brings in @EliLillyandCo as investor, raising $45M, coming 5 months after the $130 million Series B round. It was driven by new preclinical results that accelerated the timeline for starting IND-enabling studes. endpoints.news/eli-lilly-back…

Or a similar technology recently published by @altos_labs using the promoter of a senescence-related gene Cdkn2a (p16), to specifically express reprogramming factors OSK in senescent cells: pubmed.ncbi.nlm.nih.gov/39259812/

These new factors may also contribute to in vivo age reversal by reprogramming; however, controlling these powerful factors in vivo remains a challenge. They may be paired with other technologies, such as @DrMichaelWest developmentally-regulated iTR: patents.google.com/patent/WO20230…

New work by @RetroBio_ @OpenAI advances the iPSC field by using AI to make far more efficient variants of the natural Yamanaka factors, overcoming a significant obstacle in reprogramming cells to pluripotency: openai.com/index/accelera…

On September 28th, I decided to stop rapamycin, ending almost 5 years of experimentation with this molecule for its longevity potential. I have tested various rapamycin protocols including weekly (5, 6, and 10 mg dose schedules), biweekly (13 mg) and alternating weekly (6/13mg) to optimize rejuvenation and limit side effects. Despite the immense potential from pre-clinical trials, my team and I came to the conclusion that the benefits of lifelong dosing of Rapamycin do not justify the hefty side-effects (intermittent skin/soft tissue infections, lipid abnormalities, glucose elevations, and increased resting heart rate). With no other underlying causes identified, we suspected Rapamycin, and since dosage adjustments had no effect, we decided to discontinue it entirely. Preclinical and clinical research has indicated that prolonged rapamycin use can disrupt lipid metabolism and profiles [1], as well as induce insulin and glucose intolerance [2] as well as pancreatic Beta-cells toxicity [3]. Despite anecdotal evidence of rapamycin slowing down tumor growth, its effect in inhibiting natural killer cells [4]  do raise concern for anti-cancer immune surveillance and cancer risk in the longer run. Additionally, on October 27th, a new pre-print [5] indicated that Rapamycin was one of a handful of supposed longevity interventions to cause an increase/acceleration of aging in humans across 16 epigenetic aging clocks. This type of evaluation is the first of its kind, as most longevity interventions up to date have been tested against one or two aging clocks, leading to invisible biases and potential intended “cherry picking” of favorable clocks for the tested interventions. Longevity research around these experimental compounds is constantly evolving, necessitating ongoing, close observation of the research and my biomarkers which my team and I do constantly. Sources: [1] pubmed.ncbi.nlm.nih.gov/12177161/ [2]pmc.ncbi.nlm.nih.gov/articles/PMC33…. [3]diabetesjournals.org/diabetes/artic… [4]pmc.ncbi.nlm.nih.gov/articles/PMC40….

Exciting! Belmonte lab reports OSK-reprogramming of old (p16+) cells increases wound healing & the lifespan of mice without causing cancer. Bodes well for human trials @lifebiosciences beginning next year 🚀🧵 tinyurl.com/249f3tpm

I heard from Michael West that Leonard Hayflick, who discovered cellular senescence (the Hayflick limit), passed away yesterday. He was the founder of the field and will be missed. Here is a great interview of Dr. Hayflick by Dr. West. youtu.be/VtE4XKM2WBo

New preprint from the lab. Comparative analysis of previously established and novel reprogrammable mouse strains. Goal: generate new tools to achieve significant organismal rejuvenation and lifespan extension in wild type mice! biorxiv.org/content/10.110…

New @OcampoLab preprint describing interesting new reprogrammable mouse strains coming in a few dates!

🚀 “Each month, we grow increasingly confident that age is reversible.” Partial reprogramming holds incredible rejuvenating potential that could revolutionize medicine as we know it.

Initiation phase cellular reprogramming ameliorates DNA damage in the ERCC1 mouse model of premature aging frontiersin.org/articles/10.33…

Life Biosciences hoping to enter human clinical trials for rejuvenation in the eye in 2025:

Moonwalk steps out with $57m for epigenetic reprogramming platform longevity.technology/news/moonwalk-…

Aging research comes of age nature.com/articles/s4159…

“The Information Theory of Aging” was published today. Free copy @NatureAging rdcu.be/dtGSC

@JoelSercel @davidasinclair @YuanchengLu The doxycycline is used to activate OSK expression. Glaucoma-like damage was induced by micro beads which are independent of doxycycline.

Ok, you created a mouse model of glaucoma where the induced disfunction was designed to be reversible via doxycycline. Then you gave doxycycline and showed that the model worked as designed. How does this help actual glaucoma or aging which is not reversible with doxycycline administration?

Our next installment of epigenetic rejuvenation via age reversal is out: 2 months of OSK gene therapy in mice with glaucoma fully restores their vision, with no evidence of side-effects, even after prolonged use. Congrats to Bruce Ksander, @YuanchengLu, and the entire team 👏🏻🙏 tinyurl.com/mvwansz8

‘There will be a point where we solve aging – this decade is that moment in time’ @xprize founder Peter Diamandis on the biggest prize the world has ever seen – and why a successful outcome will mean we’ll all be winners. #healthspan #XPRIZE #longevity longevity.technology/news/there-wil…

Paper by @OcampoLab shows that avoiding expression of reprogramming factors in liver and intestine reduces harmful side effects. Typically, systemic OSKM expression is lethal within 1 week, but this new model allows longer term continuous expression. nature.com/articles/s4358…

Our CEO, Jerry McLaughlin, was recently a guest on the @ProgressPotent1 Podcast. He spoke with host Ira Pastor about his background in pharma, Life Bio’s work in the #AgeRelatedDisease space & more. Watch the episode here: brnw.ch/21wED2D #HealthyAging #BiotechIndustry